GBA1 Gene Mutations in α-Synucleinopathies—Molecular Mechanisms Underlying Pathology and Their Clinical Significance
International Journal of Molecular Sciences · 20.01.2023 · 24 (3) · 2044
DOI: 10.3390/ijms24032044 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 20.01.2023. Verfasst von Zuzanna Granek und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Chemistry and Biochemistry, Medical University of Lodz, Mazowiecka 5, 92-215 Lodz, Poland. Hauptthemen laut MEDLINE: Parkinson Disease, Synucleinopathies. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 159 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Lodz, National Science Center, Medical University of Lodz, Poland.
Abstract (Originalsprache)
α-Synucleinopathies comprise a group of neurodegenerative diseases characterized by altered accumulation of a protein called α-synuclein inside neurons and glial cells. This aggregation leads to the formation of intraneuronal inclusions, Lewy bodies, that constitute the hallmark of α-synuclein pathology. The most prevalent α-synucleinopathies are Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). To date, only symptomatic treatment is available for these disorders, hence new approaches to their therapy are needed. It has been observed that GBA1 mutations are one of the most impactful risk factors for developing α-synucleinopathies such as PD and DLB. Mutations in the GBA1 gene, which encodes a lysosomal hydrolase β-glucocerebrosidase (GCase), cause a reduction in GCase activity and impaired α-synuclein metabolism. The most abundant GBA1 gene mutations are N370S or N409S, L444P/L483P and E326K/E365K. The mechanisms by which GCase impacts α-synuclein aggregation are poorly understood and need to be further investigated. Here, we discuss some of the potential interactions between α-synuclein and GCase and show how GBA1 mutations may impact the course of the most prevalent α-synucleinopathies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Chemistry and Biochemistry, Medical University of Lodz, Mazowiecka 5, 92-215 Lodz, Poland.
- Department Geriatrics and Social Work, Jesuit University Ignatianum in Cracow, Kopernika 26, 31-501 Cracow, Poland.
ORCID-Profile: Zuzanna Granek, Natalia Siwecka, Wioletta Rozpędek-Kamińska
Förderung
- Medical University of Lodz
- National Science Center
- Medical University of Lodz, Poland
- Polish National Science Centre
Zitieren
APA
Granek, Z., Barczuk, J., Siwecka, N., Rozpędek-Kamińska, W., Kucharska, E., & Majsterek, I. (2023). GBA1 Gene Mutations in α-Synucleinopathies—Molecular Mechanisms Underlying Pathology and Their Clinical Significance. International Journal of Molecular Sciences, 24(3), 2044. https://doi.org/10.3390/ijms24032044
Vancouver
Granek Z, Barczuk J, Siwecka N, Rozpędek-Kamińska W, Kucharska E, Majsterek I. GBA1 Gene Mutations in α-Synucleinopathies—Molecular Mechanisms Underlying Pathology and Their Clinical Significance. International Journal of Molecular Sciences. 2023;24(3):2044. doi:10.3390/ijms24032044
BibTeX
@article{Granek2023,
author = {Granek, Zuzanna and Barczuk, Julia and Siwecka, Natalia and Rozpędek-Kamińska, Wioletta and Kucharska, Ewa and Majsterek, Ireneusz},
title = {GBA1 Gene Mutations in α-Synucleinopathies—Molecular Mechanisms Underlying Pathology and Their Clinical Significance},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {3},
pages = {2044},
doi = {10.3390/ijms24032044}
}
EUVIMED